Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Reexamination Certificate
2007-05-30
2011-12-06
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
C424S155100, C424S183100, C530S387300, C530S388800
Reexamination Certificate
active
08071072
ABSTRACT:
This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
REFERENCES:
patent: 4172124 (1979-10-01), Koprowski et al.
patent: 4861581 (1989-08-01), Epstein et al.
patent: 5171665 (1992-12-01), Hellstrom et al.
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5616468 (1997-04-01), Salmi et al.
patent: 5693322 (1997-12-01), Creekmore et al.
patent: 5693763 (1997-12-01), Codington et al.
patent: 5750102 (1998-05-01), Eisenbach et al.
patent: 5780033 (1998-07-01), Torchilin et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5849876 (1998-12-01), Linsley et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5869268 (1999-02-01), Kudo et al.
patent: 5879898 (1999-03-01), Tarin et al.
patent: 5885575 (1999-03-01), Herrlich et al.
patent: 5916561 (1999-06-01), Adolf et al.
patent: 5942417 (1999-08-01), Ni et al.
patent: 5980896 (1999-11-01), Hellstrom et al.
patent: 6180357 (2001-01-01), Young et al.
patent: 6372441 (2002-04-01), Heider et al.
patent: 6657048 (2003-12-01), Young et al.
patent: 7252821 (2007-08-01), Young et al.
patent: 2001/0003777 (2001-06-01), Young et al.
patent: 2001/0009665 (2001-07-01), Young et al.
patent: 2002/0041877 (2002-04-01), Young et al.
patent: 2002/0051780 (2002-05-01), Lindhofer et al.
patent: 2002/0160010 (2002-10-01), Herrlich et al.
patent: 2003/0103985 (2003-06-01), Adolf et al.
patent: 2004/0001789 (2004-01-01), Young et al.
patent: 2004/0101530 (2004-05-01), Young et al.
patent: 2004/0105815 (2004-06-01), Young et al.
patent: 2005/0008646 (2005-01-01), Young et al.
patent: 2005/0100542 (2005-05-01), Young et al.
patent: 2006/0216233 (2006-09-01), Young et al.
patent: 2008/0124327 (2008-05-01), Young et al.
patent: 2008/0131429 (2008-06-01), Young et al.
patent: 2008/0274049 (2008-11-01), Young et al.
patent: 2009/0004103 (2009-01-01), Young et al.
patent: WO9412631 (1994-06-01), None
patent: WO9520401 (1995-08-01), None
patent: WO0294879 (2002-05-01), None
patent: WO02082076 (2002-10-01), None
patent: WO03055515 (2003-07-01), None
patent: WO2004087205 (2004-10-01), None
ATCC search output for “PTA-4621” (p. 1; Jul. 19, 2009).
Breyer, R. et al., “Disruption of intracerebral progression of C6 rat glioblastoma by in vivo treatment with anti-CD44 monoclonal antibody”, J. Neurosurg., 92: 140-149, (Jan. 2000).
Zawadazki et al., “Blockade of Meatasis Formation by CD44-Receptor Globulin”, Int. J. Cancer, 75: 919-924 (1998).
Zahalka et al., “Lymph Node (but Not Spleen) Invasion by Murine Lymphoma Is Both CD44- and Hyaluronate Dependent”, The Journal of Immunology, 154: 5345-5355 (1995).
Wallach-Dayan et al., “CD44-dependent lymphoma cell dissemination: a cell surface supports in vitro lymphoma cell rolling on hyaluronic acid substrate and its in vitro accumulation in the peripheral lymph nodes”, Journal of Cell Science, 114: 3463-3477 (2001).
Strobel et al., “In vivo Inhibition of CD44 Limits Intra-Abdominal Spread of Human Ovarian Cancer Xenograft in Nude Mice: A Novel Role for CD44 in the Process of Peritoneal Implantation” Cancer Research, 57:1228-1232 (Apr. 1, 1997).
M. Allouche et al, “Ligation of the CD44 adhesion molecule inhibits drug-induced apoptosis in human myeloid leukemia cells”, Blood, 96(3):1187-1190 (Aug. 2000).
C. Badger et al, “Prospects for monoclonal antibody therapy of leukemia and lymphoma”, Cancer, 58:584-589 (1986).
I. Barshack et al, “CD44 expression in normal adrenal tissue and adrenal tumors”, J. Clin. Pathol., 51:52-54 (1998).
A. Begg et al, “Rapid fluorescence-based assay for radiosensitivity and chemosensitivity testing in mammalian cells in vitro”, Cancer Research, 49:565-569 (Feb. 1989).
Becton Dickinson Technical Data Sheet for L178 Clone (published Nov. 5, 2003).
E. Boven et al, “Monoclonal antibodies in cancer treatment: where do we stand after 10 years?”, Radiotherapy and Oncology, 5:109-117 (1986).
M. Chatterjee et al, “Idiotypic antibody immunotherapy of cancer”, Cancer Immunol. Imunother, 38:75-82 (1994).
M. Co et al, “Chimeric and humanized antibodies with specificity for the CD33 antigen”, J. Immunol., 148:1149-1154 (Feb. 1992).
D. Colnot et al, “Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study”, Clin. Cancer Res., 8:3401-3406 (Nov. 2002).
D. Colnot et al, “Radioimmunotherapy in patients with head and neck squamous cells carcinoma:initial experience”, Head & Neck, 23:559-565 (Jul. 2001).
D. Colnot et al, “Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck”, J. Nucl. Med., 41:1999-2010 (Dec. 2000).
D. Colnot et al, “Evaluation of limited blood sampling in a preceding 99mTC-labeled diagnostic study to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb U36 radioimmunotherapy”, J. Nucl. Med., 42(9):1364-1367 (Sep. 2001).
A. Costa et al, “Implications of disaggregation procedures on biological representation of human solid tumours”, Cell Tisue Kinet., 20:171-180 (1987).
J. Cruse et al, Illustrated Dictionary of Immunology, CRC Press, p. 280 (1995).
B. Curti, “Physical barriers to drug delivery in tumors”, Critical Reviews in Oncology/Hematology, 14:29-39 (1993).
A. Daar et al, “The membrane antigens of human colorectal cancer cells:demonstration with monoclonal antibodies of heterogeneity within and between tumours and of anomalous expression of HLA-DR”, Eur. J. Cancer Clin. Oncol., 19(2):209-220 (1983).
S. Dairkee et at, “Partial enzymatic degradation of stroma allows enrichment and expansion of primary breast tumor cells”, Cancer Research, 57:1590-1596 (Apr. 1997).
R. De Bree et al, “Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients”, British J. Cancer, 75(7):1049-1060 (1997).
R. De Bree et al, Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer, Clin. Can. Res., 1:591-598 (Jun. 1995).
S. Denning et al, “Antibodies against the CD44 p80, lymphocyte homing receptor molecule augment human peripheral blood T cell activation”, J. Immunol., 144:7-15 (Jan. 1990).
G. Dermer, “Another anniversary for the war on cancer”, Bio/Technology, 12:320 (Mar. 1994).
R. Dillman, “Antibodies as cytotoxic therapy”, J. Clin. Oncol., 12(7):1497-1515 (Jul. 1994).
R. Dillman, “Monoclonal antibodies for treating cancer”, Annals of Internal Medicine, 111:592-603 (1989).
M. Disis et al, “HER-2
eu protein: a target for antigen-specific immunotherapy of human cancer”, Advances in Cancer Research, 71:343-371 (1997).
H. Drexler, “Recent results on the biology of Hodgkin and Reed-Stemberg cells”, Leukemia and Lymphoma, 9:1-25 (1993).
Eckhardt et al., “Developmental Therapeutics: Successes and Failures of Clinical Trial Designs of Targeted Compounds”; ASCO Educational Book, 39th Annual Meeting, 2003, pp. 209-219.
M. Embleton, “Monoclonal antibodies to osteogenic sarcoma antigensȁ
Cechetto Lisa M.
Findlay Helen P.
Hahn Susan E.
McConkey Fortunata
Vasquez Maximiliano
Bristol Lynn
Fish & Richardson P.C.
Hoffmann-La Roche Inc.
LandOfFree
Cytotoxicity mediation of cells evidencing surface... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytotoxicity mediation of cells evidencing surface..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxicity mediation of cells evidencing surface... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4311391